Integrative Physician's Perspective

Medical Oncology
It is a privilege to be able to feature a contribution to this Tumor Board by Drs Supriya Gupta and Nicholas Vogelzang of the University of Chicago Section of Hematology/Oncology. Under Vogelzang's leadership, the research team at this institution has made a very significant contribution to our knowledge of this disease, which is, as discussed in this Tumor Board, remarkably worrisome for patients and physicians alike. With 25% to 50% of patients exhibiting distant metastases at initial diagnosis with renal cancer, and with 40% of patients developing metastases after surgery for primary disease, renal cell carcinoma (RCC) can be extremely lethal. The availability of immunotherapies that can produce fairly durable remissions, such as IL-2, as discussed by Gupta and Vogelzang, relieves the concerns raised by the fact that RCC appears to be resistant to cytotoxic chemotherapies. They point out that none of the single-agent chemotherapies currently available have shown effectiveness in patients who have failed immunotherapy. They also raise very interesting possibilities for the use of biochemically and immunologically targeted agents such as monoclonal antibodies, dendritic cell therapies, and angiogenesis inhibitors, all of which are still in relatively early stages of research for RCC. Today, we are seeing much more widespread use of combination therapies involving more than one chemotherapeutic agent and even combinations of chemotherapy with molecular target drugs in other cancers. As an integrative physician, I generally find myself in favor of multifaceted approaches in both therapeutic agents and complementary therapies. Perhaps combinations of newer therapies will provide a path for better control in the relapsed RCC patient in the future.
Gupta and Vogelzang not only present a useful assessment of the use of the major immunotherapies, but they also provide some very useful educational background in their discussion of the differences between the Robson system of classification and the TNM system, pointing out that the TNM system actually has a better correlation with prognosis for the individual patient. Information of this type is most helpful in aiding the practicing clinician in assessing the literature on this disease.
We are also very privileged to have a contribution from Dr Hardev Pandha, a senior lecturer in medical oncology at the University of London, who provides an international perspective on the treatment of RCC and brings some different elements into this discussion. Pandha mentions the apparent regression of the isolated pulmonary lesion after nephrectomy. This is an example of the regression of metastases following surgery that Gupta and Vogelzang present as the basis of the immunological treatment of RCC. Pandha provides interesting details on the spontaneous regression phenomenon, which occurs in probably less than 1% of cases but at every sort of metastatic site. He also mentions that these regressions usually relapse eventually, and further lung metastases were indeed seen in this patient after several months.
Pandha summarizes yet another tumor-grading system for RCC, the Furhman system, widely used internationally. Fuhrman's system classifies tumors into 4 grades according to their degree of differentiation. His discussion of the significance of disease-free interval and metastatic sites is also of interest: the relatively short disease-free interval of this patient is not promising, although the fact that relapse occurred in the lungs may contribute to a better prognosis. He later notes that the most powerful prognostic factor for patients with metastatic disease is performance status. Since this patient has a Karnofsky score of 90%, her good performance status may bode well for her eventual outcome. The strong relevance of performance status for survival raises an interesting question: do the health-promoting recommendations of most integrative medicine programs (eg, good diet, fitness) improve performance status in patients? And if so, does improved performance status affect survival times? This is certainly a question worthy of further exploration.
Pandha's descriptions of treatment recommendations that might be made for this patient are intriguing and highlight some differences in US and international practices in cancer treatment. A clinical trial being conducted in the United Kingdom at this time employs IL-2, 5FU, and INF-α. Although the combination of cytokines is reported to result in higher toxicity, the use of protracted rather than bolus 5FU appears to be resulting in higher response rates in some patients. Most interestingly, Pandha states that INF-α would be the treatment normally recommended for this patient in the United Kingdom and Europe, while IL-2 would be recommended in the United States (and indeed was given the most discussion by Gupta and Vogelzang). This apparently reflects a greater concern over toxicity and side effects in Europe.
Naturopathy
The naturopathic colleges in the United States continue to put out sharp clinicians who have much to offer cancer patients. Dan Rubin exemplifies the clinical breadth of naturopaths in his well-done piece. Some readers may be startled to see Dr Rubin's discussions of recommending computed tomography (CT) scans, medications, and other medical procedures, since he is not an MD. Rubin has been practicing in Arizona, one of the states in which medical regulations afford naturopaths a much wider degree of practice than in many other states, so he is well within the limits of practice allowed him. His mention of bisphosphonate therapy as a consideration for the first visit, for instance, is thus both appropriate and interesting in view of recent research in this area, 1 with the possibility of metastatic involvement in the left scapular region. Bisphosphonates may also have some impact on soft tissue metastases.
All good medicine should, as Rubin describes, address the individual as a person first and a patient second, and this is certainly consistent with naturopathic practice as we usually see it in these Tumor Boards. His initial attempt to develop a working hypothesis about the cause of her disease and disease progression as a basis for the assessment of lifestyle patterns and therapeutic plans and his multifaceted approach to treatment is consonant with naturopathic medical approaches and with integrative medicine in general. His 7 mechanisms for cancer therapy provide a particularly interesting theoretical framework for his treatment recommendations. This prevents his multiple therapeutic interventions from becoming simply a scattershot deployment of every natural therapy available, which is what often results when patients attempt to "integrate" their own medical care by visiting a variety of complementary and alternative practitioners. Using a specific theoretical framework of this sort helps the integrative practitioner both by making a multidisciplinary program coherent and by making sure that all important aspects of cancer treatment are addressed in the treatment plan. A therapeutic plan that includes multiple strategies is particularly appropriate for a fast-growing tumor, when there is little time to experiment. There should be less reluctance to administer an agent with little toxicity, such as vitamin D, under such circumstances. Still, caution needs to be exercised when using some supplements with patients with bone metastases, as they may contribute to hypercalcemia. 2 Rubin mentions the interesting findings on IGF-IR and its effect on RCC prognosis. Since dietary factors are suspected to play a role in high levels of IGF-IR expression, one can only wonder when, not if, dietary interventions will eventually become part of modern oncology, alongside agents, such as the new AG538 might give rise to. 3 Good medicine is simply going to demand that the relevance of such interventions be taken into account.
In the discussion of mental and emotional factors, Rubin mentions his perception that most persons with cancer have experienced significantly stressful life events in the 18 months prior to diagnosis. This is a pattern commonly witnessed by others in the integrative medicine community and is not limited to oncology. My own experience is that such events have typically taken place during the 5 years prior to diagnosis. However, I would be cautious about attributing any kind of causality to these events. The problem is that such stressful events occur at a high rate among noncancer patients as well, making this an interesting but incomplete observation. What is important is that Rubin, like other naturopaths and integrative practitioners, is asking the question in the first place. Background levels of life stress prior to the cancer diagnosis certainly impinge on the cancer patient's experience and may contribute to overall high levels of stress during cancer treatment. It behooves all practitioners to be sensitive to the impact that the patient's life outside the clinic may have on the emotionally and physically exhausting experience of cancer treatment.
Rubin asserts in his very last paragraph that cancer treatment in the metastatic setting allows for a certain leniency to depart from clinical trial data in searching for agents or treatments that would prolong survival. I see some justification for this stance in the use of lifestyle strategies, supplements, and botanicals that are known to have low toxicity. I am not sure that I concur with him as far as pharmaceutical agents and other conventional treatments are concerned, particularly those that are more toxic. The point deserves and demands further discussion but will have to be delayed until a later issue of this journal.
Psycho-oncology
The final contribution to this Tumor Board is from Ms Penny Block from the Block Center for Integrative Cancer Care and reflects the practices that would be typical in cytokine treatment of renal cell carcinoma at our center. The importance of depression as a side effect of cytokine treatment emphasizes the relevance of Rubin's final dimension of treatment, the mentalemotional aspect. Health care professionals need to be alert to depressive symptoms in cancer patients, as they can be easily missed. Our use of regularly scheduled psychological evaluations at the Block Center arises from this concern. We tend to treat depression arising during cytokine treatment with exercise and dietary interventions initially, as mentioned in Ms Block's contribution. We find that such treatments usually resolve treatment-related depression adequately and without the potential pharmacological complications of adding yet another drug to a patient's treatment regimen. However, because of the potential for emergence of severe depression during cytokine treatment, the usefulness of botanical or pharmaceutical agents for depression should not be overlooked.
